While the applicability of the Immunome Discovery Engine is broad, Immunome’s focus is on the development of new therapies for oncology and infectious diseases.
Our primary focus areas are in the oncology and infectious disease spaces. We are leveraging the insights from the Immunome Discovery Engine to guide the discovery of future oncology pipeline assets and enable future strategic collaborations and additional value creation.
Our platform is also being leveraged in the fight against COVID-19. The Immunome Discovery Engine is being used to interrogate the immune response of COVID-19 “super-responders”, individuals who have successfully fought the virus. We aim to isolate antibodies that initiate multiple viral clearance mechanisms simultaneously, like neutralization, complement fixation, and phagocytosis, among others. We will combine a mixture of these antibodies to develop a Biosynthetic Convalescent Plasma (BCP) that can be of potential use in both treatment and prophylactic settings. We are currently engaged in the research and development of an effective antibody mixture.